A recent study from Finland reports that a protein kinase called LRRK2 is hyperactive in skin samples from Parkinson’s disease patients which leads to a decrease in protein synthesis.

The University of Turku has entered into a licensing agreement with an international pharma company related to targeting of CIP2A oncoprotein. …

Jane and Aatos Erkko Foundation has awarded 975 000 € for research led by professor Jukka Westermarck and focused on phosphorylation mechanism under RAS oncoprotein.

Dissertation: Kartiek Kanduri, M.Sc. 5.6.2020, medical microbiology and immunology Kartiek Kanduri discovered several novel factors that regulate T-cell differentiation and function, Understanding the regulation of immune response is central for…

Picture by  Fusion Medical Animation on Unsplash. We are happy to announce the success of a number of research groups that received funding from the…

The Turku Bioscience and BioCity Turku common scientific advisory board visited the centre at the end of February. During their visit, they met reseach programme representatives and core facility personnel.

Despite of continuous development of breast cancer treatments, metastases of the most aggressive breast cancer types are still a significant and growing medical problem. Together with a research group at…

Now that BioCity has a brand new look, the guiding star of Turku Bioscience came up on the black wall. Now it is easier to find us, just follow the logo! Here…

We are proud to announce that Sigrid Juselius foundation has granted numerous grants to Turku Bioscience researchers. Most sums mentioned below are for year 2020-2021. However funds have been granted…